Preclinical evaluations have revealed KN046’s enhanced binding affinity for PD-L1 compared to conventional monoclonal antibodies, coupled with its unique capacity to deplete tumor-infiltrating regulatory T cells (Tregs) within the tumor microenvironment.26 This dual mechanism of action potentiates antitumor immunity through concurrent enhancement of effector T-cell activity and attenuation of immunosuppressive cellular components. The gene discussed is CD274; the disease is neoplasm.